What side effects does ticagrelor cause?

Ticagrelor causes hemorrhagic complications such as the risk of bleeding, typical of the entire drug class. Additionally, dyspnea (shortness of breath) frequently occurs in 10–20% of patients due to ticagrelor's structural similarity to adenosine and its effect on adenosine metabolism.

Is metabolic activation required for ticagrelor?

No, the drug is not a prodrug, possesses intrinsic pharmacological activity, and does not require prior hepatic conversion to initiate its action.

Why must ticagrelor be taken twice daily?

The dosing frequency is due to pharmacokinetics—rapid elimination of the drug and the reversible nature of its binding to platelet receptors.

What causes dyspnea during treatment with the drug?

The symptom develops in 10–20% of patients due to the chemical similarity between the active substance and adenosine, as well as its effect on the metabolism of this nucleoside.

Home › Pharmacology › Ticagrelor: Mechanism, Pharmacokinetics and Effects

Ticagrelor

*Ticagrelor*

For medical students2 min readUpdated 2026-10-10

Ticagrelor (Brilinta) is an oral antiplatelet agent belonging to the cyclopentyltriazolopyrimidine chemical class, used in clinical practice since 2010. It selectively blocks platelet receptors and is prescribed for the prevention of thrombotic events in acute coronary syndrome.

Trade nameBrilinta

TargetPlatelet P2Y12 receptors

Dosing regimenTwice daily

MetabolismLiver, CYP3A4 enzyme

Chemical Structure and Pharmacodynamics

The drug is a cyclopentyltriazolopyrimidine derivative with a chemical structure close to adenosine. Unlike thienopyridines (clopidogrel), ticagrelor is not a prodrug and does not require metabolic activation to exert its therapeutic effect.

The drug's action is based on non-competitive and reversible allosteric binding to platelet P2Y12 receptors. It binds to a receptor site distinct from the ADP binding pocket. Due to the reversibility of this binding, platelet function recovery occurs faster after drug discontinuation compared to thienopyridines.

Advantages over Traditional Agents

A key difference and clinical benefit of ticagrelor is the absence of resistance linked to genetic factors:

Drug efficacy is not compromised in patients with low activity of the CYP2C19 isoenzyme.
The antiplatelet effect develops faster than with clopidogrel.
Receptor binding is reversible, making it easier to predict bleeding risks if discontinuation is necessary.

Pharmacokinetics and Dosing

Following oral administration, the substance is rapidly absorbed in the gastrointestinal tract, with a bioavailability of 36%. Metabolism occurs in the liver with the active participation of the CYP3A4 enzyme, producing an active metabolite that also possesses antiplatelet properties.

Due to relatively rapid elimination from the body and termination of action, the therapeutic regimen requires administration twice daily.

Side Effects and Clinical Features

The primary systemic risk of therapy, common to the entire pharmacological class, is hemorrhagic complications (tendency toward bleeding and hemorrhage).

A unique specific side effect is dyspnea (shortness of breath), observed in 10–20% of patients. This phenomenon is due to the drug's structural similarity to adenosine and its direct effect on purine metabolism.

Mnemonic

Ticagrelor is NOT a prodrug (no activation needed), causes dyspnea (adenosine trace), and is taken TWICE a day.

Frequently asked questions

What side effects does ticagrelor cause?: Ticagrelor causes hemorrhagic complications such as the risk of bleeding, typical of the entire drug class. Additionally, dyspnea (shortness of breath) frequently occurs in 10–20% of patients due to ticagrelor's structural similarity to adenosine and its effect on adenosine metabolism.
Is metabolic activation required for ticagrelor?: No, the drug is not a prodrug, possesses intrinsic pharmacological activity, and does not require prior hepatic conversion to initiate its action.
Why must ticagrelor be taken twice daily?: The dosing frequency is due to pharmacokinetics—rapid elimination of the drug and the reversible nature of its binding to platelet receptors.
What causes dyspnea during treatment with the drug?: The symptom develops in 10–20% of patients due to the chemical similarity between the active substance and adenosine, as well as its effect on the metabolism of this nucleoside.

Go deeper

Pharmacodynamic differences between ticagrelor and thienopyridines (clopidogrel and prasugrel)
Role of cytochrome CYP3A4 and the impact of inducers/inhibitors on drug concentration
Ticagrelor interaction with P-glycoprotein and concurrent pharmacotherapy
Management strategies for patients who develop dyspnea during Brilinta therapy
Selection criteria for antiplatelet therapy in acute coronary syndrome